Account Info
Log Out
English
Back
Download
Log in to access Online Inquiry
Quotes
Detailed Quotes
Company Overview
Company ProfileCompany Executives
Financial Analysis
Main CompositionKey IndicatorsFinancial Statement
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 01244 3D MEDICINES-B > Financial Statement > Income statement
01244 3D MEDICINES-B
69.000
+0.200+0.29%
Income statement Balance sheet Cash flow
YOY
Do not show
Hide blank lines
(FY)2021/12/31(FY)2020/12/31
Turnover
-- 60.26M -- --
Operating income
60.26M
Cost of sales
-- -4.28M -- --
Operating expenses
-4.28M
Gross profit
55.98M
Selling expenses
-- -42.83M -- --
Administrative expenses
-272.47% -150.96M 1.37% -40.53M
Research and development expenses
-40.61% -371.16M -15.07% -263.97M
Revaluation surplus
-199.07% -954.74M -- -319.23M
-Changes in the fair value of other assets
-199.07% -954.74M -- -319.23M
Impairment and provision
-- -130K -- --
-Other impairment is provision
-- -130K -- --
Special items of operating profit
198.66% 3.54M 89.25% -3.59M
Operating profit
-132.78% -1.46B -106.43% -627.32M
Financing cost
81.04% -1.53M 47.01% -8.06M
Earning before tax
-130.07% -1.46B -98.29% -635.38M
After-tax profit from continuing operations
-130.07% -1.46B -98.29% -635.38M
Earning after tax
-130.07% -1.46B -98.29% -635.38M
Minority profit
-- -27.73M -- --
Profit attributable to shareholders
-125.71% -1.43B -98.29% -635.38M
Basic earnings per share
-163.60% -36.72 -34.20% -13.93
Diluted earnings per share
-163.60% -36.72 -34.20% -13.93
Currency Unit
CNYCNY
Accounting Standards
IASIAS
Audit Opinions
Unqualified OpinionUnqualified Opinion
Auditor
Ernst & YoungErnst & Young

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report，MOM=(current period - last period)/last period *100%

Company Overview More
3D Tumor Biotechnology Shanghai Co Ltd is a Chinese company mainly engaged in the development of commercial oncology products and drug candidates. The company's main product pipeline includes immuno-oncology monotherapy, drug candidates with mechanisms of action suitable for in-line combinations, and pain management assets. The company's core product is envolizumab, an anti-PD-L1 drug injected subcutaneously. The company also has several clinical-stage drug candidates, including the peptide cancer vaccine 3D189, the GAS6 decoy receptor 3D229, and the fibroblast growth factor receptor (FGFR) 3D185. The company mainly operates in the domestic market.
CEO： Zhaolong Gong
Market： Hong Kong motherboard
Listing Date： 12/15/2022
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist